Critical Reviews in Oncology Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy
Eribulin mesylate (hereafter referred to as “eribulin”), a synthetic analog of halichondrin B, is a microtubule-targeting chemotherapeutic agent (Mani and Swami, 2010; Swami et al., 2012). It can inhibit mitotic spindle formation by targeting the growth phase of microtubules, which results in increased apoptosis and decreased cell prolife ration (Jordan et al., 2005). This new mechanism of action is distinct from those traditional tubulin-targeting agents such as taxanes, paclitaxel and vinblastine (Dybdal-Hargreaves et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Bin Zhao, Hong Zhao, Jiaxin Zhao Source Type: research

Bone Marrow Versus Peripheral Blood as a Graft Source for Haploidentical Donor Transplantation in Adults Using Post-Transplant Cyclophosphamide —A Systematic Review and Meta-Analysis
Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT, particularly for patients using post-transplant cyclophosphamide (PTCy), which is the standard therapy. However, to date, no meta-analysis focusing on this issue has been published. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 11, 2018 Category: Cancer & Oncology Authors: Xiaotong Yu, Liping Liu, Zhenwei Xie, Chongya Dong, Libo Zhao, Jingru Zhang, Hong-Hu Zhu, Jian Gu Source Type: research

Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma
Pimozide is currently being used in clinic as a neuroleptic and exerts versatile biological actions. Pimozide is a cationic amphiphilic drug (CAD); CADs block the synthesis of neutral lipids, impair cholesterol homeostasis of cancer cells and increase accumulation of diacylglycerol-3-phosphate. Pimozide exerts tumoricidal activity which was first shown for melanoma and neuroblastoma via proposed anti- dopaminergic effects. Recently, pancreas cancers are shown to elevate dopamine receptor-2 synthesis, which is blocked by pimozide leading growth inhibition. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 11, 2018 Category: Cancer & Oncology Authors: Ilhan Elmaci, Meric A. Altinoz Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 9, 2018 Category: Cancer & Oncology Source Type: research

Tafro syndrome: critical review for clinicians and pathologists
TAFRO is an acrostic and includes thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R) and organomegaly (O) (Takai et al., 2013). TAFRO syndrome has been described firstly by Takai in Japanese patients. However TAFRO cases have been reported from US, Europe and other countries (Takai et al., 2010; Iwaki et al., 2016; Abdo et al., 2014). Three major and at least one minor criteria and exclusion of infectious, rheumatologic and neoplastic diseases are required for the diagnosis of TAFRO. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Paydas Semra Source Type: research

Anthropometric factors and non-Hodgkin ’s lymphoma risk: Systematic review and meta-analysis of prospective studies
The associations between anthropometric factors and non-Hodgkin ’s lymphoma (NHL) risk remain inconclusive. A meta-analysis was performed to clarify these associations. PubMed and Web of Science were searched for relevant prospective observational studies. A random-effects model was used to generate the summary relative risks (RRs) with 95% confidence interval s (CIs). A total of 22 prospective cohort studies, with over 20,000 NHL cases, were included in the present meta-analysis. The summary RRs of NHL risk were 1.06 (95% CI 1.03, 1.09) for each 5 kg/m2 increase in body mass index (BMI), 1.11 (95% CI 1.07, 1.16) for e...
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Khemayanto Hidayat, Hui-Juan Li, Bi-Min Shi Source Type: research

A revisited concept. Tumors: Wounds that do not heal
In 1986, Harold F. Dvorak, Professor of Pathology at Harvard Medical School Boston, published an essay in the New England Journal of Medicine entitled “Tumors: Wounds that do not heal” pointed out that similarities exist between tumor stroma generation and wound healing. Cancers share many features in common with tissue regeneration, including immune response, cell proliferation, cell migration, tissue remodeling, and cell death. In this revie w article, I analyzed the importance and the limits of this important concept, which confirm the close relationship between apparently different biological processes. (Source: Cr...
Source: Critical Reviews in Oncology Hematology - June 6, 2018 Category: Cancer & Oncology Authors: Domenico Ribatti, Roberto Tamma Source Type: research

Molecular targets of celastrol in cancer: Recent trends and advancements
In the past few decades, the interest in medicinal plants and their bioactive molecules has extensively grown, and many of such agents exhibit diverse effects on suppressing the development and progression of neoplasms, both in vitro as well in vivo animal models (Kashyap et al., 2016d; Kumar et al., 2016; Tuli et al., 2014). It is widely believed that such substances can provide a plausible alternative to synthetic drugs due to their potency, safety, and lower cost (Hansen et al., 2011). One of such potential natural agent is celastrol, a quinine methide triterpenoid. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 5, 2018 Category: Cancer & Oncology Authors: Dharambir Kashyap, Ajay Sharma, Hardeep Singh Tuli, Katrin Sak, Tapan Mukherjee, Anupam Bishayee Source Type: research

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): towards a less dismal future?
The onset of Brain Metastases (BM) is proportionally greater in lung cancer than in other solid tumors (Barnholtz-Sloan et al., 2004), with significant impact on patients performance status (PS) and prognosis (Ali and Goffin, 2013). Synchronous or metachronous central nervous system (CNS) spread occurs in about 20% and 40% of Non-Small Cell Lung Cancer (NSCLC) cases, respectively (Langer and Mehta, 2005; S ørensen et al., 1988). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 24, 2018 Category: Cancer & Oncology Authors: Frega Stefano, Bonanno Laura, Guarneri Valentina, Conte Pier Franco, Pasello Giulia Source Type: research

Manipulating macrophage polarization and function using classical HDAC inhibitors: implications for autoimmunity and inflammation
Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases. Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury. However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis. Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors. (Source: Critical...
Source: Critical Reviews in Oncology Hematology - May 23, 2018 Category: Cancer & Oncology Authors: Asadollah Mohammadi, Atefeh Sharifi, Reza Pourpaknia, Saeed Mohammadian, Amirhossein Sahebkar Source Type: research

Perioperative Chemotherapy for Urothelial Carcinoma of the Upper Urinary Tract: A Systematic Review and Meta-Anaysis
Upper tract urothelial carcinomas are rare malignancies with differences in anatomy and biology requiring therapeutic strategies that differ from bladder cancer. The role of perioperative systemic therapy in this disease remains uncertain with limited data to support its use. A systematic review of the literature and meta-analysis was therefore undertaken to provide more information and guide clinical practice (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 21, 2018 Category: Cancer & Oncology Authors: Richard W. Gregg, Francisco E. Vera-Badillo, Christopher M. Booth, Aamer Mahmud, Michael Brundage, Michael J. Leveridge, Timothy P. Hanna Source Type: research

Glutathione system in animal model of solid tumors: From regulation to therapeutic target
Glutathione (GSH) is involved in scavenging reactive oxygen species (ROS) to maintain antioxidant defenses and regulate redox-dependent cell signaling (Masella et al., 2005). GSH is also involved in several metabolic processes, including the synthesis of proteins and DNA, enzyme activity, metabolism, gene expression, signal transduction, and the intensification of cytoplasmic and transmembrane transport (Meister and Anderson, 1983; Zmorzy ński et al., 2015). The detoxification of xenobiotics and endogenous compounds is another relevant function of GSH (Ballatori et al., 2009). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 21, 2018 Category: Cancer & Oncology Authors: Claudia Rita Corso, Alexandra Acco Source Type: research

Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers
Gynecologic cancer is any cancer that starts in a woman ’s reproductive organs such as ovary, uterine, vagina and vulva (Coukos et al., 2016). Each gynecologic cancer is unique, with different clinical symptoms, risk factors, prevention strategies and treatments (Alkatout et al., 2015; Colombo and Peiretti, 2010; Yang et al., 2016). Multiple treatment modalities for gynecologic cancers include surgery, chemotherapy, and radiation, depending on the kind of cancer and how far it has spread (Cortez et al., 2017; Ventriglia et al., 2017; van Poelgeest et al., 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 18, 2018 Category: Cancer & Oncology Authors: Chiara Di Tucci, Michele Carlo Schiavi, Pierangelo Faiano, Ottavia D ’Oria, Giovanni Prata, Valentina Sciuga, Andrea Giannini, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici Source Type: research

A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival
Due to its fatal consequences, esophageal cancer is one of the most severe types of cancers (Umar and Fleischer, 2008). With more than 450,000 new cases and 400,000 deaths, it is the eighth most common cancer and the sixth leading cause of death from cancer in the world (Ferlay et al., 2010; Pennathur et al., 2013). Because of its aggressive nature, the prognosis of the disease is poor. Despite improvements in treatment interventions, the five-year survival of the disease is approximately 20 percent (Ferlay et al., 2010; Mao et al., 2011; Shibata et al., 2011). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Amin Doosti-Irani, Kourosh Holakouie-Naieni, Abbas Rahimi-Foroushani, Mohammad Ali Mansournia, Peiman Haddad Source Type: research

Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities
Primary central nervous system lymphoma (PCNSL) occurs within the special sanctuary of the blood-brain barrier and is therefore regarded as an ‘immune-privileged (IP)’ lymphoma. The majority of PCNSLs are diffuse large B-cell lymphomas (DLBCLs) (Louis et al., 2007; Bhagavathi and Wilson, 2008), which originate from late germinal centre (GC) B-cells (Deckert et al., 2014; Courts et al., 2008; Coupland and Damato, 2008; Alizadeh et al., 2000) or early post-GC B-cells with blocked terminal differentiation (Camilleri-Broet et al., 2006; Braggio et al., 2015; Montesinos-Rongen et al., 2004; Coupland and Damato, 2008). (Sour...
Source: Critical Reviews in Oncology Hematology - May 17, 2018 Category: Cancer & Oncology Authors: Laura S. Hiemcke-Jiwa, Roos J. Leguit, Tom J. Snijders, N. Mehdi Jiwa, Jonas. J.W. Kuiper, Roel A. de Weger, Monique C. Minnema, Manon M.H. Huibers Source Type: research